G1 Therapeutics, Inc.
NASDAQ:GTHX
7.15 (USD) • At close September 17, 2024
 Overzicht | Financiële gegevens
 | Bedrijfsnaam | G1 Therapeutics, Inc. | 
| Symbool | GTHX | 
| Munteenheid | USD | 
| Prijs | 7.16 | 
| Beurswaarde    |  377,748,712 | 
| Dividendpercentage    |  0% | 
| 52-weken bereik | 1.08 - 7.19 | 
| Industrie | Biotechnology | 
| Sector | Healthcare | 
| CEO | Mr. John E. Bailey Jr. | 
| Website | https://www.g1therapeutics.com | 
An error occurred while fetching data.
Over G1 Therapeutics, Inc.
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive 
 Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)







